JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: In this study, we provide pre-clinical evidence that combination treatment with a selective JAK2 inhibitor (BMS-911543) and TKI more effectively eradicates IM-insensitive BCR-ABL+ cells and primary CML stem/progenitor cells compared to either BMS-911543 or TKI alone, suggesting a potential new treatment option for patients with CML.